Improving Medication Safety, Costs, and Patient Outcomes


2024 Texas Society of Health-System Pharmacists Annual Seminar

Kalahari Resorts & Conventions
3001 Kalahari Blvd.
Round Rock, TX 78665

Room: Kalahari Bamboo/Acacia 
Breakfast provided

Medication errors associated with the administration of the wrong dose and/or wrong concentration are believed to be more prevalent when frontline practitioners are provided with a parenteral product that requires additional manipulation (partial doses, reconstitution, or dilution) at the bedside.

Many organizations, including ISMP, ASHP, and APSF have recommended to avoid the unnecessary, error-prone complexity of IV push medication preparation and administration, calling for all stakeholders to re-evaluate current products administered and standardize as much as possible to ready-to-administer (RTA) formulations and concentrations.

Using examples of events that have been reported to the ISMP National Medication Errors Reporting Program (ISMP MERP) and data from cost-effectiveness research studies, faculty will describe the key vulnerabilities when IV medications require manipulation at the bedside that have led to errors and patient harm. The speakers will review data from studies that compare the cost and safety of manufacturer-prepared prefilled ready-to-administer (RTA) products compared to traditional vial-and-syringe products. Additionally, new evidence-based research data showing the relationship between improved patient outcomes and specific opioid product availability will be discussed.

Intended Audience:

  • Pharmacists
  • Pharmacy Technicians

Learning Objectives:

Following completion of this activity, participants will be able to:

  1. Describe the risks associated with preparation and administration of IV medications that are manipulated in perioperative and procedural care settings. 
  2. Compare studies evaluating the cost and safety of manufacturer-prepared ready-to-administer (RTA) products versus traditional vial-and-syringe products. 
  3. Recognize new evidence demonstrating improved patient outcomes when providers are presented with RTA products. 

Introduction and Overview:

Christina Michalek, BS, RPh, FASHP, Director of Membership and PSO, ISMP


Risks Associated with the Preparation and Administration of IV Medications

Christina Michalek, BS, RPh, FASHP, Director of Membership and PSO, ISMP

Comparing Costs and Safety Implications of Ready-to-Administer (RTA) Products and Traditional Vial-and-Syringe Products

John B. Hertig, PharmD, MS, CPPS, FASHP, Vice-Chair and an Associate Professor of Pharmacy Practice in the Butler University College of Pharmacy and Health Sciences

The Effect of Opioid Vial Sizes on Patient Outcomes

Satya Krishna Ramachandran, MD, Associate Professor, Harvard Medical School, Anesthesiologist, Beth Israel Deaconess Medical Center

Funds for this program have been provided by an unrestricted grant from Fresenius Kabi. 

Space is limited and pre-registration is encouraged. Pre-registration is for planning purposes only and seating will be available on a first-come, first-served basis. Breakfast will be provided. 

CE Accreditation

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Institute for Safe Medication Practices. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. 
(Universal Activity Number - JA4008073-9999-24-069-L05-P/T)
Type of Activity: Knowledge